Biogen/$BIIB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Ticker

$BIIB
Sector
Primary listing

Employees

7,605

Biogen Metrics

BasicAdvanced
$22B
14.24
$10.45
0.14
-

What the Analysts think about Biogen

Analyst ratings (Buy, Hold, Sell) for Biogen stock.

Bulls say / Bears say

In July 2025, Biogen announced a $2 billion investment to expand its North Carolina manufacturing plants—adding fill-finish, automation, and AI systems—to boost domestic production ahead of possible U.S. drug tariffs.
In August 2025, the FDA approved an at-home, weekly injectable version of Leqembi—called Leqembi IQLIK—making treatment easier to administer and expected to increase patient adoption.
In April 2025, the European Commission approved Leqembi for early-stage Alzheimer’s, making it the first EU-approved drug targeting the root cause of the disease, with analysts projecting peak sales of over $900 million in the 2030s.
In Q1 2025, Biogen’s multiple sclerosis drug sales fell by 11%, putting more pressure on its main business as competition increases.
The company booked a $165 million licensing charge in Q1 2025 from a deal with Stoke Therapeutics, leading it to lower its full-year EPS guidance to $14.50–$15.50.
Leqembi brought in just $52 million in U.S. sales for Q1 2025, showing sluggish uptake due to ongoing concerns about pricing, effectiveness, and required monitoring for side effects.
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.

Biogen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Biogen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BIIB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs